Clinical analysis of 36 cases of advanced non-small cell lung cancer (NSCLC) with performance status (PS) scores between 2 and 4
10.3760/cma.j.issn.0253-3766.2017.11.009
- VernacularTitle: 36例体力状况评分≥2分的晚期非小细胞肺癌患者的临床分析
- Author:
Yinyin QIN
1
;
Dehua ZHANG
1
;
Xinqing LIN
1
;
Ming OUYANG
1
;
Jiexia ZHANG
1
;
Zhanhong XIE
1
;
Yiqian LIU
1
;
Shiyue LI
1
;
Chengzhi ZHOU
1
Author Information
1. The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Diseases, National Clinical Research Center for Respiratory, Guangzhou respiratory health research institute, Guangzhou 510120, China
- Publication Type:Clinical Trail
- Keywords:
Lung neoplasms;
Performance status;
Drug therapy;
Treatment outcome
- From:
Chinese Journal of Oncology
2017;39(11):855-861
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the treatment of advanced non-small cell lung cancer (NSCLC) with performance status (PS) scores between 2 and 4, in order to improve the diagnosis and treatment of these patients.
Methods:A total of 36 patients with advanced NSCLC with hypoxemia were reviewed. The clinical data of disease characteristics, etiology, complications, manifestation, therapy, progression, and secondary biopsy were collected. The clinical efficacy was graded according to the Response Evaluation Criteria In Solid Tumors (RECIST): complete response (CR), partial response (PR), stable disease (SD) and disease progression (PD).
Results:All patients had hypoxemia, of whom 86.1% (31 patients) had complications and 55.6% (20 patients) had noninvasive ventilator for respiratory support. 77.8% (28 cases) received broad-spectrum antibiotic treatment, and 78.6% of them got lung osmotic relief after the anti-infection treatment. 15 cases received bedside fiberoptic bronchoscopy suction, of whom two cases were treated with airway stent deposition due to airway obstruction, four cases with thoracic drainage, four cases with anticoagulation, and one with thrombolytic therapy. After these supportive treatment, the PS score of these patients decreased from 3.4±0.5 to 2.5±0.7, while SPO2 improved from (89.0±5.2)% to (95.0±3.5)%. As first-ling anti-cancer treatment, nine patients were administrated with targeted medicine orally, 13 patients with a combined chemotherapy of pemetrexed plus bevacizumab or carboplatin, eight patients with paclitaxel plus carboplatin, four patients with gemcitabine plus carboplatin, and two patients with docetaxel plus gemcitabine. In the first response evaluation, there were one case of CR, 23 cases of PR, four cases of SD, and eight cases of PD, with a clinical benefit rate of 66.7% and a disease control rate of 77.8%. A total of 22 patients experienced disease progression, of whom eight cases had a secondary biopsy and six cases had gene sequencing. Of these 36 patients, 10 (27.8%) patients survived at the last follow-up, with a progression-free survival of (10.0±6.5) months.
Conclusion:Besides prompt anti-cancer treatment and best supportive treatment should be incorporated to improve PS and improve outcome.
